Genialis, a computational precision medicine company unraveling complex biology to find new ways to address disease, today announced the launch of ResponderID™, a new AI/ML-enabled platform specifically for use in clinical biomarker discovery. ResponderID™ may be implemented to support Pharma drug pipelines and diagnostic test product portfolios from conception to market.

Read the press release in its entirety here.

Share this story, choose your platform!